Comprehensive analysis of excision repair complementation group 1, glutathione S-transferase, thymidylate synthase and uridine diphosphate glucuronosyl transferase 1A1 polymorphisms predictive for treatment outcome in patients with advanced gastric cancer treated with FOLFOX or FOLFIRI

Oncology Reports

Volumn 22, Issue 1, 2009, Pages 127-136

  Seo, Bong Gun ^a   Kwon, Hyuk Chan ^a   Oh, Sung Yong ^a   Lee, Suee ^a   Kim, Sung Gun ^a   Kim, Sung Hyun ^a   Han, Hoon ^a   Kim, Hyo Jin ^a  

^a Dong A University College of Medicine   (South Korea)

Author keywords

Elutathione S transferase; Excision repair complementationgroup 1; FOLFIRI; FOLFOX; Gastric cancer; Thymidylate synthase; Uridine diphosphate glucuronosyl transferase 1A1

Indexed keywords

EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; FLUOROURACIL; FOLINIC ACID; GENOMIC DNA; GLUCURONOSYLTRANSFERASE 1A1; GLUTATHIONE TRANSFERASE; IRINOTECAN; OXALIPLATIN; THYMIDYLATE SYNTHASE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DNA EXTRACTION; DRUG RESPONSE; ENZYME ANALYSIS; FEMALE; GENE FREQUENCY; GENETIC VARIABILITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PHARMACOGENETICS; POLYMERASE CHAIN REACTION; PREDICTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM; STOMACH ADENOCARCINOMA; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; DISEASE PROGRESSION; DNA-BINDING PROTEINS; ENDONUCLEASES; FEMALE; FLUOROURACIL; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE FREQUENCY; GENOTYPE; GLUCURONOSYLTRANSFERASE; GLUTATHIONE TRANSFERASE; HUMANS; KAPLAN-MEIERS ESTIMATE; LEUCOVORIN; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; PATIENT SELECTION; PHENOTYPE; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; PREDICTIVE VALUE OF TESTS; STOMACH NEOPLASMS; THYMIDYLATE SYNTHASE; TIME FACTORS; TREATMENT OUTCOME;

EID: 68249140418     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or_00000415     Document Type: Article

References (51)

1. Chang JC: Perspectives on stomach cancer. J Korean Med Sci 9: 277-280, 1994.
2. Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 55: 74-108, 2005.
3. Cuschieri A, Weeden S, Fielding J, et al: Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Surgical Co-operative Group. Br J Cancer 79: 1522-1530, 1999.
4. Schipper DL and Wagener DJ: Chemotherapy of gastric cancer. Anticancer Drugs 7: 137-149, 1996.
5. Oh SY, Kwon HC, Lee S, et al: A Phase II study of oxaliplatin with low-dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFOX-4) for gastric cancer patients with malignant ascites. Jpn J Clin Oncol 37: 930-935, 2007.
6. Bouche O, Raoul JL, Bonnetain F, et al: Randomized multi-center phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: a Federation Francophone de Cancerologie Digestive Group Study - FFCD 9803. J Clin Oncol 22: 4319-4328, 2004.
7. Kim SG, Oh SY, Kwon HC, et al: A phase II study of irinotecan with bi-weekly, low-dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFIRI) as salvage therapy for patients with advanced or metastatic gastric cancer. Jpn J Clin Oncol 37: 744-749, 2007.
8. Metzger R, Leichman CG, Danenberg KD, et al: ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. J Clin Oncol 16: 309-316, 1998.
9. Shirota Y, Stoehlmacher J, Brabender J, et al: ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J Clin Oncol 19: 4298-4304, 2001.
10. Park DJ, Stoehlmacher J, Zhang W, Tsao-Wei DD, Groshen S and Lenz HJ: A Xeroderma pigmentosum group D gene polymorphism predicts clinical outcome to platinum-based chemotherapy in patients with advanced colorectal cancer. Cancer Res 61: 8654-8658, 2001.
11. Gurubhagavatula S, Liu G, Park S, et al: XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small cell lung cancer patients treated with platinum chemotherapy. J Clin Oncol 22: 2594-2601, 2004.
12. Suk R, Gurubhagavatula S, Park S, et al: Polymorphisms in ERCC1 and grade 3 or 4 toxicity in non-small cell lung cancer patients. Clin Cancer Res 11: 1534-1538, 2005.
13. Goekkurt E, Hoehn S, Wolschke C, et al: Polymorphisms of glutathione S-transferases (GST) and thymidylate synthase (TS) - novel predictors for response and survival in gastric cancer patients. Br J Cancer 94: 281-286, 2006.
14. Ruzzo A, Graziano F, Kawakami K, et al: Pharmacogenetic profiling and clinical outcome of patients with advanced gastric cancer treated with palliative chemotherapy. J Clin Oncol 24: 1883-1891, 2006.
15. Mathijssen RH, van Alphen RJ, Verweij J, et al: Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin Cancer Res 7: 2182-2194, 2001.
16. Humerickhouse R, Lohrbach K, Li L, Bosron WF and Dolan ME: Characterization of CPT-11 hydrolysis by human liver carboxylesterase isoforms hCE-1 and hCE-2. Cancer Res 60: 1189-1192, 2000.
17. Hua D, Huang ZH, Mao Y and Deng JZ: Thymidylate synthase and thymidine phosphorylase gene expression as predictive parameters for the efficacy of 5-fluorouracil-based adjuvant chemotherapy for gastric cancer. World J Gastroenterol 13: 5030-5034, 2007.
18. Wei J, Zou Z, Qian X, et al: ERCC1 mRNA levels and survival of advanced gastric cancer patients treated with a modified FOLFOX regimen. Br J Cancer 98: 1398-1402, 2008.
19. Kawakami K, Omura K, Kanehira E and Watanabe Y: Polymorphic tandem repeats in the thymidylate synthase gene is associated with its protein expression in human gastrointestinal cancers. Anticancer Res 19: 3249-3252, 1999.
20. Kawakami K, Salonga D, Park JM, et al: Different lengths of a polymorphic repeat sequence in the thymidylate synthase gene affect translational efficiency but not its gene expression. Clin Cancer Res 7: 4096-4101, 2001.
21. Mandola MV, Stoehlmacher J, Zhang W, et al: A 6 bp polymorphism in the thymidylate synthase gene causes message instability and is associated with decreased intratumoral TS mRNA levels. Pharmacogenetics 14: 319-327, 2004.
22. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205-216, 2000.
23. Huang MJ, Kua KE, Teng HC, Tang KS, Weng HW and Huang CS: Risk factors for severe hyperbilirubinemia in neonates. Pediatr Res 56: 682-689, 2004.
24. Zhou W, Gurubhagavatula S, Liu G, et al: Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy. Clin Cancer Res 10: 4939-4943, 2004.
25. Harries LW, Stubbins MJ, Forman D, Howard GC and Wolf CR: Identification of genetic polymorphisms at the glutathione S-transferase Pi locus and association with susceptibility to bladder, testicular and prostate cancer. Carcinogenesis 18: 641-644, 1997.
26. Arand M, Muhlbauer R, Hengstler J, et al: A multiplex polymerase chain reaction protocol for the simultaneous analysis of the glutathione S-transferase GSTM1 and GSTT1 polymorphisms. Anal Biochem 236: 184-186, 1996.
27. Wilson MD, Ruttan CC, Koop BF and Glickman BW: ERCC1: a comparative genomic perspective. Environ Mol Mutagen 38: 209-215, 2001.
28. Dabholkar M, Bostick-Bruton F, Weber C, Bohr VA, Egwuagu C and Reed E: ERCC1 and ERCC2 expression in malignant tissues from ovarian cancer patients. J Natl Cancer Inst 84: 1512-1517, 1992.
29. Dabholkar M, Vionnet J, Bostick-Bruton F, Yu JJ and Reed E: Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy. J Clin Invest 94: 703-708, 1994.
30. Park DJ, Zhang W, Stoehlmacher J, et al: ERCC1 gene polymorphism as a predictor for clinical outcome in advanced colorectal cancer patients treated with platinum-based chemotherapy. Clin Adv Hematol Oncol 1: 162-166, 2003.
31. Liu D, O'Day SJ, Yang D, et al: Impact of gene polymorphisms on clinical outcome for stage IV melanoma patients treated with biochemotherapy: an exploratory study. Clin Cancer Res 11: 1237-1246, 2005.
32. Isla D, Sarries C, Rosell R, et al: Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small cell lung cancer. Ann Oncol 15: 1194-1203, 2004.
33. Viguier J, Boige V, Miquel C, et al: ERCC1 codon 118 polymorphism is a predictive factor for the tumor response to oxaliplatin/ 5-fluorouracil combination chemotherapy in patients with advanced colorectal cancer. Clin Cancer Res 11: 6212-6217, 2005.
34. Stoehlmacher J, Park DJ, Zhang W, et al: A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/ oxaliplatin combination chemotherapy in refractory colorectal cancer. Br J Cancer 91: 344-354, 2004.
35. Oguri T, Fujiwara Y, Katoh O, et al: Glutathione S-transferase-pi gene expression and platinum drug exposure in human lung cancer. Cancer Lett 156: 93-99, 2000.
36. Stoehlmacher J, Park DJ, Zhang W, et al: Association between glutathione S-transferase P1, T1, and M1 genetic polymorphism and survival of patients with metastatic colorectal cancer. J Natl Cancer Inst 94: 936-942, 2002.
37. Hohaus S, Di Ruscio A, Di Febo A, et al: Glutathione Stransferase P1 genotype and prognosis in Hodgkin's lymphoma. Clin Cancer Res 11: 2175-2179, 2005.
38. Shu XO, Gao YT, Cai Q, et al: Genetic polymorphisms in the TGF-beta 1 gene and breast cancer survival: a report from the Shanghai Breast Cancer Study. Cancer Res 64: 836-839, 2004.
39. Davies SM, Robison LL, Buckley JD, et al: Glutathione S-transferase polymorphisms and outcome of chemotherapy in childhood acute myeloid leukemia. J Clin Oncol 19: 1279-1287, 2001.
40. DeMichele A, Aplenc R, Botbyl J, et al: Drug-metabolizing enzyme polymorphisms predict clinical outcome in a nodepositive breast cancer cohort. J Clin Oncol 23: 5552-5559, 2005.
41. Sweeney C, Nazar-Stewart V, Stapleton PL, Eaton DL and Vaughan TL: Glutathione S-transferase M1, T1 and P1 polymorphisms and survival among lung cancer patients. Cancer Epidemiol Biomarkers Prev 12: 527-533, 2003.
42. Lee JM, Wu MT, Lee YC, et al: Association of GSTP1 polymorphism and survival for esophageal cancer. Clin Cancer Res 11: 4749-4753, 2005.
43. Iyer L, Hall D, Das S, et al: Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism. Clin Pharmacol Ther 65: 576-582, 1999.
44. *28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenomics J 2: 43-47, 2002.
45. Tan BR and McLeod HL: Pharmacogenetic influences on treatment response and toxicity in colorectal cancer. Semin Oncol 32: 113-119, 2005.
46. Han JY, Lim HS, Shin ES, et al: Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small cell lung cancer treated with irinotecan and cisplatin. J Clin Oncol 24: 2237-2244, 2006.
47. Peters GJ, Backus HH, Freemantle S, et al: Induction of thymidylate synthase as a 5-fluorouracil resistance mechanism. Biochim Biophys Acta 1587: 194-205, 2002.
48. Pullarkat ST, Stoehlmacher J, Ghaderi V, et al: Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy. Pharmacogenomics J 1: 65-70, 2001.
49. Mandola MV, Stoehlmacher J, Muller-Weeks S, et al: A novel single nucleotide polymorphism within the 5+pm tandem repeat polymorphism of the thymidylate synthase gene abolishes USF-1 binding and alters transcriptional activity. Cancer Res 63: 2898-2904, 2003.
50. Marcuello E, Altes A, Del Rio E, Cesar A, Menoyo A and Baiget M: Single nucleotide polymorphism in the 5′ tandem repeat sequences of thymidylate synthase gene predicts for response to fluorouracil-based chemotherapy in advanced colorectal cancer patients. Int J Cancer 112: 733-737, 2004.
51. Ishida Y, Kawakami K, Tanaka Y, Kanehira E, Omura K and Watanabe G: Association of thymidylate synthase gene polymorphism with its mRNA and protein expression and with prognosis in gastric cancer. Anticancer Res 22: 2805-2809, 2002.